NImmune Biopharma and BioTherapeutics Collaborate on Advanced Immunology Therapeutics

NImmune Biopharma, a late-stage precision immunology company, has entered a research collaboration with BioTherapeutics Inc., a biotech company specializing in advanced computational modeling and clinical experimentation. The partnership will strengthen NImmune’s capabilities by giving them access to BioTherapeutics’ preclinical services, regulatory expertise, and unique animal models, including specialized pig models for inflammatory bowel disease (IBD).

Dr. Raquel Hontecillas, Chief Scientific Officer of BioTherapeutics, expressed excitement over the collaboration, emphasizing how their sophisticated computational and preclinical services, including proprietary autoimmune disease models, will aid the development of vital therapeutics. This partnership builds on a collaborative ecosystem involving the NIMML Institute, which has demonstrated success with the development of NX-13, later acquired by AbbVie.

Dr. Bassaganya-Riera, CEO of NImmune, highlighted the strategic nature of the partnership, combining BioTherapeutics’ validated models with NImmune’s expertise in translating scientific discoveries into innovative medicines. The collaboration aims to fast-track the clinical development of drug candidates targeting autoimmune diseases like ulcerative colitis, Crohn’s disease, psoriasis, and rheumatoid arthritis.